Patents by Inventor Hye-Ran Yeon

Hye-Ran Yeon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL CHIMERIC ANTIGEN RECEPTOR (CAR) HAVING ENHANCED FUNCTIONS
    Publication number: 20250032541
    Abstract: The present invention relates to a novel chimeric antigen receptor comprising a CD99L2 region, which is known to play a key role in cell adhesion and migration, as a backbone of the chimeric antigen receptor, an immune cell comprising the same, and the uses thereof. CD99L2-based CAR-T cells exhibit enhanced T-cell activity and tumor treatment efficiency compared to conventional CAR-T cells, and thus can be useful in immune cell therapy for the treatment of cancer.
    Type: Application
    Filed: August 26, 2022
    Publication date: January 30, 2025
    Applicant: TICAROS CO., LTD
    Inventors: Kyungho CHOI, Eun-Young CHOI, Giri NAM, Hanna CHANG, Hyeonji LIM, Hye-Ran YEON, Hyung-Bae PARK
  • Immune synapse-stabilizing chimeric antigen receptor (CAR) T cell
    Patent number: 11965014
    Abstract: The present invention relates to a novel chimeric antigen receptor comprising a CD99 region which participates in immune synapse stabilization as a backbone of the chimeric antigen receptor, an immune cell comprising the same, and the uses thereof. CD99-based CAR-T cells are capable of forming very stable immune synapses with tumor cells compared to conventional backbone-based CAR-T cells and can exhibit improved tumor therapeutic efficiency, so they can be useful for immune cell therapy for the treatment of cancer.
    Type: Grant
    Filed: July 28, 2021
    Date of Patent: April 23, 2024
    Assignee: TICAROS CO., LTD.
    Inventors: Kyungho Choi, Eun-Young Choi, Giri Nam, Hyung-Bae Park, Ji-Eun Lee, Hye-Ran Yeon
  • IMMUNE SYNAPSE-STABILIZING CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL
    Publication number: 20230118625
    Abstract: The present invention relates to a novel chimeric antigen receptor comprising a CD99 region which participates in immune synapse stabilization as a backbone of the chimeric antigen receptor, an immune cell comprising the same, and the uses thereof. CD99-based CAR-T cells are capable of forming very stable immune synapses with tumor cells compared to conventional backbone-based CAR-T cells and can exhibit improved tumor therapeutic efficiency, so they can be useful for immune cell therapy for the treatment of cancer.
    Type: Application
    Filed: July 28, 2021
    Publication date: April 20, 2023
    Applicant: TICAROS CO., LTD.
    Inventors: Kyungho Choi, Eun-Young Choi, Giri Nam, Hyung-Bae Park, Ji-Eun Lee, Hye-Ran Yeon